TY - JOUR
T1 - Pediatric rhabdomyosarcoma of the head and neck
AU - Kraus, Dennis H.
AU - Saenz, Nicholas C.
AU - Gollamudi, Smitha
AU - Heller, Glenn
AU - Moustakis, Margarita
AU - Gardiner, Sharon
AU - Gerald, William L.
AU - Ghavimi, Fereshteh
AU - LaQuaglia, Michael P.
PY - 1997/11
Y1 - 1997/11
N2 - PURPOSE: Survival for pediatric rhabdomyosarcoma has improved with the use of multidrug chemotherapy and external beam radiotherapy. This study was performed to determine survival in a cohort of patients treated on one of three multidrug treatment protocols for head and neck rhabdomyosarcoma and to identify factors that place patients at risk for treatment failure. METHODS: Pertinent prognostic variables including age, sex, subsite of origin, resectability, and TNM stage were analyzed by the Kaplan-Meier methods with comparisons between variables performed using the Prentice-Wilcoxon test statistic. RESULTS: Overall 5-year survival was 74% (95% confidence interval 64% to 84%). Local failure accounted for the cause of death in 10 patients, and 8 died of disseminated disease. On univariate analysis, each variable contributing to the TNM staging system was significant in determining survival; invasiveness (P = 0.01), size (P = 0.02), nodal metastases (P <0.01), and distant disease (P <0.01). CONCLUSION: Survival has improved for head and neck rhabdomyosarcoma treated with multimodality therapy. Patients with advanced-stage disease are at greatest risk for treatment failure and require the most aggressive therapy.
AB - PURPOSE: Survival for pediatric rhabdomyosarcoma has improved with the use of multidrug chemotherapy and external beam radiotherapy. This study was performed to determine survival in a cohort of patients treated on one of three multidrug treatment protocols for head and neck rhabdomyosarcoma and to identify factors that place patients at risk for treatment failure. METHODS: Pertinent prognostic variables including age, sex, subsite of origin, resectability, and TNM stage were analyzed by the Kaplan-Meier methods with comparisons between variables performed using the Prentice-Wilcoxon test statistic. RESULTS: Overall 5-year survival was 74% (95% confidence interval 64% to 84%). Local failure accounted for the cause of death in 10 patients, and 8 died of disseminated disease. On univariate analysis, each variable contributing to the TNM staging system was significant in determining survival; invasiveness (P = 0.01), size (P = 0.02), nodal metastases (P <0.01), and distant disease (P <0.01). CONCLUSION: Survival has improved for head and neck rhabdomyosarcoma treated with multimodality therapy. Patients with advanced-stage disease are at greatest risk for treatment failure and require the most aggressive therapy.
UR - http://www.scopus.com/inward/record.url?scp=0030723118&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030723118&partnerID=8YFLogxK
U2 - 10.1016/S0002-9610(97)00171-2
DO - 10.1016/S0002-9610(97)00171-2
M3 - Article
C2 - 9374237
AN - SCOPUS:0030723118
SN - 0002-9610
VL - 174
SP - 556
EP - 560
JO - American journal of surgery
JF - American journal of surgery
IS - 5
ER -